

# Naveen Yarlagadda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3694559/publications.pdf>

Version: 2024-02-01

17  
papers

277  
citations

1937685

4  
h-index

1588992

8  
g-index

17  
all docs

17  
docs citations

17  
times ranked

707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 808-817.	5.2	14
2	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	0
3	Clinical characteristics of testicular extramedullary involvement in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E77-E81.	4.1	1
4	Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E341-E344.	4.1	4
5	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. <i>Leukemia Research</i> , 2021, 110, 106714.	0.8	2
6	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. <i>Blood Cancer Journal</i> , 2020, 10, 70.	6.2	27
7	Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 59-61.	0.5	0
8	Hemophagocytic lymphohistiocytosis in adults. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 326-330.	0.5	5
9	Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. , 2020, 24, .		8
10	Treatment Strategies and Outcomes for Patients with Peripheral T-Cell Lymphoma and Its Subtypes. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
11	1593. Recurrence of <i>Clostridium difficile</i> Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S498-S499.	0.9	0
12	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7095-7107.	2.0	187
13	The Mutational Landscape of Primary Plasma Cell Leukemia. <i>Blood</i> , 2018, 132, 114-114.	1.4	2
14	Characteristics, associations, and outcomes of hemophagocytic lymphohistiocytosis: Retrospective data over a period of 13 years from a university hospital.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19563-e19563.	1.6	0
15	Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit. <i>Blood</i> , 2018, 132, 5825-5825.	1.4	0
16	High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience. <i>Urology</i> , 2014, 83, 1129-1134.	1.0	24
17	Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 911-915.	4.9	3